Literature DB >> 10699497

Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth.

J Cao1, Y Sun, T Berglindh, B Mellgård, Z Li, B Mårdh, S Mårdh.   

Abstract

Colonization of the human stomach by Helicobacter pylori is associated with the development of gastritis, duodenal ulcer, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. H. pylori-antigen-binding single-chain variable fragments (ScFv) were derived from murine hybridomas producing monoclonal antibodies and expressed as a g3p-fusion protein on a filamentous M13 phage. The recombinant ScFv-phage reacted specifically with a 30-kDa monomeric protein of a H. pylori surface antigen preparation and by means of immunofluorescence microscopy the phage was shown to bind to both the spiral and coccoid forms of the bacterium. In vitro, the recombinant phage exhibited a bacteriocidal effect and inhibited specifically the growth of all the six strains of H. pylori tested. When H. pylori was pretreated with the phage 10 min before oral inoculation of mice, the colonization of the mouse stomachs by the bacterium was significantly reduced (P<0.01). The results suggest that genetic engineering may be used to generate therapy-effective phages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699497     DOI: 10.1016/s0304-4165(00)00005-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

Review 1.  Pharmacokinetic principles of bacteriophage therapy.

Authors:  Robert J H Payne; Vincent A A Jansen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 3.  Molecular modification of T4 bacteriophage proteins and its potential application - review.

Authors:  A Kurzepa; K Dabrowska; K Switała-Jeleń; A Górski
Journal:  Folia Microbiol (Praha)       Date:  2009-03-29       Impact factor: 2.099

4.  Isolation of high-affinity single-chain antibodies against Mycobacterium avium subsp. paratuberculosis surface proteins from sheep with Johne's disease.

Authors:  Sven Berger; Dominik Hinz; John P Bannantine; J Frank T Griffin
Journal:  Clin Vaccine Immunol       Date:  2006-09

Review 5.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 6.  Phage therapy and photodynamic therapy: low environmental impact approaches to inactivate microorganisms in fish farming plants.

Authors:  Adelaide Almeida; Angela Cunha; Newton C M Gomes; Eliana Alves; Liliana Costa; Maria A F Faustino
Journal:  Mar Drugs       Date:  2009-07-30       Impact factor: 5.118

7.  Generation and characterization of human monoclonal scFv antibodies against Helicobacter pylori antigens.

Authors:  Nicole Reiche; Andreas Jung; Thomas Brabletz; Tanja Vater; Thomas Kirchner; Gerhard Faller
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 8.  Bacteriophages and phage-derived proteins--application approaches.

Authors:  Zuzanna Drulis-Kawa; Grazyna Majkowska-Skrobek; Barbara Maciejewska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 9.  Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.

Authors:  Zuzanna Drulis-Kawa; Grazyna Majkowska-Skrobek; Barbara Maciejewska; Anne-Sophie Delattre; Rob Lavigne
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

10.  Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in catfish.

Authors:  Krishna Khairnar; Mahendra P Raut; Rajshree H Chandekar; Swapnil G Sanmukh; Waman N Paunikar
Journal:  BMC Vet Res       Date:  2013-12-26       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.